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Macrophages are highly plastic innate immune cells that can be polarized into a range of 
phenotypes. They have important roles in physiological homeostasis and innate immunity. A 
subset of anti-inflammatory macrophages has been found to infiltrate the tumor microenvironment, 
promote tumor immune evasion, initiation, growth, and metastasis. To elucidate the recruitment 
and polarization of these tumor associated macrophages, an in vivo mouse model of immune 
infiltration, in vitro models of recruitment, and ex vivo bone marrow derived macrophage (BMDM) 
studies have been carried out.  
Using a syngeneic orthotopic model of mouse pancreatic cancer, it was found that 
macrophages are preferentially enriched at both primary site and distal organs during tumor 
development. CD4+ and CD8+ T lymphocyte but not CD45R+ B lymphocyte were also enriched at 
the primary site. It was further speculated that majority of these macrophages were recruited from 
circulating monocytes based on their proximity to blood vessels.  
Cancer cell paracrine effects on immune cell motility were then evaluated. MDA-MB-231 
did not have chemoattraction on human monocyte cell line U937, however, these cancer cells 
reduced U937 motility. The effects of cancer conditioned media on BMDM motility were then 
evaluated. Motility data were fitted to the Anisotropic Persistent Random Walk model. 
Hierarchical clustering showed the cytokine induced M2 (but not M1) BMDM had significantly 
higher motility and lower heterogenicity. The cancer cell conditioned media treated BMDMs had 
consistent motility profiles with that of naïve M0 group.  
Lastly, cancer cell conditioned media can modulate macrophage mRNA and morphology. 
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Chapter 1 – Introduction  
1.1 Overview of Immune System 
 We live in a world dominated by microorganisms. All living beings must evolve ways of 
defending themselves from potentially pathogenic foreign bodies. Not only is the immune system 
not unique to humans, the first primitive immune system likely existed millions of years before 
modern humans emerged. 
 Humans and other mammals have evolved a complex immune system that communicates 
within a network or small molecules, proteins, cells, vasculatures, and organs1,2. This tightly 
regulated network is responsible for defense against pathogens, communication with microbiota, 
and maintenance of tissue homeostasis3–5. The immune system can be divided into two major 
branches, the innate immune system and the adaptive immune system.  
 The innate immune system is composed of a noncellular component made up of plasma 
proteins, and a cellular component consisting of phagocytic cells and innate lymphoid cells2,6. The 
plasma proteins known as the complement system can rapidly trigger proteolytic cascades to 
cripple invading microbes while also modulating innate and adaptive immune cell activations6. 
Phagocytes in the innate immune system recognize Pathogen-Associated Molecular Patterns 
(PAMPs) through Toll-Like Receptors (TLR)7,8. Through complex interactions with scavenger 
receptors, these cells can engulf pathogens and debris from dead cells. The phagocytosed antigens 





presentation to T cells7,9. While macrophages participate in bridging the innate and adaptive 
immune systems, dendritic cells (DCs) are the most efficient antigen presenting cells1,9.  
 Adaptive immune system is  slower acting in comparison, it consists highly specific B- and 
T-lymphocytes. Adaptive immune system assembles antigen specific recognition structures by 
shuffling somatic gene elements, and subsequently selecting for cells with optimal antigen binding 
capacities during lymphocyte maturations2,10. These processes, termed V(D)J recombination and 
clonal selection respectively, are capable of generating unique antigen binding motifs on the scale 
of ~1011 while simultaneously limiting autoreactive lymphocytes1,11–13.  
 Immune system also maintains memories. It has long been shown that B- and T- 
lymphocytes can give raise to memory cells that are capable of self-renewing and sustaining 
antigen specific immunity up to the lifetime14–16. This immunological memory provides efficient 
defense against reoccurring infections and is critical for prophylactic vaccine developments. In the 
recent times, it was further demonstrated innate immune cells such as monocytes, macrophages, 
and natural killer cells (NKs) are also capable of maintaining immunological memories termed 
“trained immunity”17,18. Although circulating monocytes have short lifespan (~24 hours), their 
trained immunity can last for months through epigenetic modification of bone marrow 






1.2 Overview of Macrophages  
1.2.1 Macrophage Receptors and Functions 
 Macrophages are professional phagocytes and antigen presenting cells. Along with other 
phagocytic cells such as monocytes, DCs, neutrophils, and mast cells, macrophages express a 
multitude of scavenger and pattern recognition receptors (PPRs) (Table 1)7. Through complex 
interactions, these receptors can recognize damage associated molecular patterns (DAMPs) or 
PAMPs from cellular debris and invading microbes. Macrophages therefore maintain a critical role 
on initiating innate immunity and maintaining tissue homeostasis.  
 
Table 1. Selective Macrophage Surface Receptors 
Receptor Class Target Function Ref 
CD36 Scavenger 
Oxidized LDL, 
diacyl fatty acids 
Phagocytosis of apoptotic cells, 







Phagocytosis of apoptotic cells 
20 
MACRO Scavenger CpG-ODNs 
Bacterial recognition, positive 




LPS, LTA, PGN, 
Phospholipids 
Recognition of apoptotic cells, 










clearance, antigen presentation, 
pathogen recognition, 

























Ig Superfamily Sialic acid 
May be involved in host cell 
recognition  
20 
Siglec-10 Ig Superfamily CD24 
Phagocytic checkpoint, blockade 
of CD24 to Siglec10 interaction 
leads to phagocytosis of CD24+ 
cancer cells 
26 
SIRPα Ig Superfamily CD47 
Phagocytic checkpoint, 








Heterodimer of CD11b and 







Binds C5a, complement 









LTA, PGN, viral 
proteins, fungal 
mannans 







PAMP recognition  
8,23 













Recruitment of monocytes, 















Regulation of macrophage 
proliferation and survival 
29 
 
1.2.2 Development of Macrophages 
 Macrophages are found in a wide range of tissue types with diverse functions30,31. 
Microglial cells maintaining homeostasis of the brain, splenic red pulp macrophages recycling red 
blood cells, and peritoneal cavity macrophage facilitating IgA productions are all examples of 
tissue resident macrophage funcitons30,31. Unlike the circulatory pool of monocytes that 
differentiated from bone marrow progenitors, most of tissue resident macrophages are of the 
embryonic origin (Figure 1) 30. These cells are capable of self-renewal and proliferation which is 
likely a result of shared transcription factors PU.1, C/EBP, and MAF30. Osteoclasts are essential 
for bone remodeling, while it is not well understood if these cells originated from embryonic tissue, 
it was shown that monocytes can differentiate into osteoclast31. Moreover, the circulatory 
monocytes can also serve as an emergency pool; in cases of severe inflammatory injury, monocytes 






Figure 1. Macrophage Development and Function  
Macrophages are derived from two lineages, embryonic and monocytic. Most of tissue resident macrophages 
are generated from embryonic precursors, whereas monocytes are circulatory and serve as a progenitor pool in 
the event of severe inflammatory injuries. During development, cells from embryonic origin enter various tissue 
microenvironments, adapt and proliferate within the local niches, and self-renew continuously throughout the 
lifespan. Monocyte progenitors are of hematopoietic stem cell linage, they reside in bone marrow with longevity.  
 
1.2.3 Macrophage Polarization 
 
 Macrophages also have remarkable plasticity. Historic understanding defines two polar 
opposite states, classically activated M1 or pro-inflammatory phenotype, and alternatively 





actually multiple phenotypically stable and distinguishable states of polarized macrophages, and 
their transcriptomic signatures range across a spectrum33–35. For instance, within the anti-
inflammatory branch, M2a is polarized by TH2 cytokines interleukin-4 (IL-4) and interleukin-13 
(IL-13), M2c is stimulated by interleukin-10 (IL-10), and M2f by engulfing apoptotic cells22,36. 
Functional outcomes of these macrophages are different, M2a promotes angiogenesis by secreting 
platelet-derived growth factor BB (PDGF-BB), M2c promotes matrix remodeling through matrix 
metalloproteinase (MMP) expressions, and M2f inhibits inflammation though autocrine/paracrine 
signaling36–38. Surprisingly, the physiological roles assigned to classical M1/M2 paradigm can 
overlap too. While M2 phenotype is traditionally associated with tissue homeostasis, Graney and 
colleagues recently demonstrated that classical M1 macrophages also promote vascularization by 
inducing pro-angiogenesis genes in endothelial cells36. To that extent, we defined M1 and M2-like 
macrophage phenotypes based on the activation stimuli, markers, and function (Figure 2)22,36,38–43. 
 It is important to note that macrophages and myeloid derived dendritic cells share 
numerous transcriptional regulations, surface marker expressions, and functional features7,44. It is 
not readily possible to distinguish these cells of the mononuclear phagocyte system, therefore the 
newly proposed nomenclature calls for classification by ontogeny45. For the scope of this thesis, 
human monocytic cell line U937 derived macrophages and murine primary bone marrow derived 






Figure 2. Classification of Macrophage Phenotypes 
Macrophages are classified into a pro-inflammatory M1 phenotype and a range of M2-like phenotypes. 
Historically defined binary paradigm of M1 M2 polarization does not accurately depict the diverse macrophage 
phenotypes. Here, M2a, M2b, M2c, and M2d have well understood activation signals, although physiological 
functions may overlap. M2f (or M2eff) macrophages arise from engulfment of apoptotic cells, a process known 
as efferocytosis. Upon activation, M2f macrophages downregulate pro-inflammatory cytokines such as IL-1β, 
IL-8 and GM-CSF through autocrine and paracrine signaling. Tissue resident macrophages maintain diverse 
phenotypes and functions (Figure 1). TAMs are considered M2-like here for its compacity to suppress antitumor 
immunity and promote intertumoral vascularization. There are also arguments for TAM not being a macrophage 
subset since it does not confer a steady state phenotype. The image shown was the maximum intensity projection 
of a U937 derived macrophage under 3-D quantitative phase imaging, a result of collaboration with Dr. Ishan 
Barman.  
1.3 Tumor Associated Macrophages 
 Macrophages are among the most abundant cells types in tumor microenvironments 
(TMEs)40. Despite their prominent role in innate immunity, tumor infiltrating macrophages are not 
usually tumoricidal31,41. In fact, tumor associated macrophages (TAMs) have been shown to 





chronic inflammation that aids the initiation of malignancies, suppress T lymphocyte activities to 
prevent immunogenic cancer cell killing, promote angiogenesis to maintain tumor growth, and 
degrade ECM network to improve cancer cell dissemination (Figure 3)31,41,46. Although TAMs 
may share some gene expression features with M1 macrophages, they are widely recognized as 
anti-inflammatory (M2-like)33.  
 Given their abundance in TMEs and trainable plasticity, TAMs has been regarded as a 
promising therapeutic target. Current clinical studies includes both small molecules and antibody 
drugs aimed at obliterating TAMs, preventing monocyte recruitments, re-educating TAMs towards 
pro-inflammatory phenotype, or blocking phagocytosis checkpoints29. Notably, a PI3Kγ signaling 
pathway targeted drug (Ibrutinib) intended to reprogram TAMs and reduce myeloid infiltration is 
under phase III clinical trial for metastatic pancreatic adenocarcinoma (PDAC) treatment 
(combination with gemcitabine and nab-paclitaxel, NCT02436668)29. Elucidation of macrophage 
mediated tumor immune evasion therefore has significant merits in immuno-oncology.  
 The pathological functions of TAMs are growing clear, but their polarization from naïve 
phenotypes remains to be fully characterized. In recent years, there are some promising results 
suggesting chemokine signaling, metabolic regulation, and checkpoint escape are some immune 
evasion mechanism26,47–50. For instance, Myosin II in tumor invasive fronts cross-talk with IL-
1α/NF-κB to release TAM-polarizing cytokines and chemokines50. It was also shown cancer cell 
secreted retinoic acid can induce monocyte differentiations into macrophages preferentially over 
DCs, and its blockage results in enhanced anti-tumor T cell immunity49. Our results suggest that 








Figure 3. Roles of Tumor Associated Macrophages 
Tumor associated macrophages holds diverse roles in tumorigenesis. The TAMs secreted cytokines  and 
chemokines can promote tumor initiation and metastasis. Widely accepted as M2-like, TAMs can also suppress 
anti-cancer T cell immunity and promote tumor vascularization. For immune suppression, both direct 
suppression such as checkpoint mediated escape and indirect suppression involving regulatory T cell have been 
shown. Furthermore, tumor size is depended on the available nutrient and oxygen transport to the core, under 
poor vasculature network, hypoxia can switch on the production of pro-angiogenic factors in TAMs whereby 
further tumor growth is sustained. This figure was reprinted from the work of Yang & Zhang under the Creative 






1.4 Tumor – Immune Interaction  
1.4.1 Cancer Immunoediting 
 An essential prerequisite for both innate and adaptive immunity is the ability to 
discriminate self from nonself2. During anti-bacterial or anti-fungal immunity, immune systems 
can recognize conserved endotoxins, sugars, or membrane structures (Table 1) as foreign. 
However, anticancer immunity can be more intricate due to the vastly diverse cancerous cell types 
with varying degree of tumorigenic potential; in addition, the complex TME also dictates cancer 
cell fates and degree of immune cell infiltrations51,52. Besides clonal evolution (a process where 
cancer cells randomly accumulate mutations and become more or less advantageous at survival 
and proliferation), “cancer immunoediting” also contributes to the tumor heterogenicity and 
evolution of cancer cells52,53. Cancer immunoediting refers to the idea that immune surveillance 
acts as an evolutionary selection pressure for cancer cells, the resulting “edited” tumor should only 
be composed of immunologically undetected cancer cells54. Effectively, cancer immunoediting 
can lead to three outcomes: 1) complete cancer rejection due to immunogenic cancer cell death, 2) 
an equilibrium between cancer cells and immune system which leads to long term cancer 
dormancy, and 3) cancer immune evasion, which leads to local or systematic outbreak of cancer 
growth55,56. Although cancer dormancy and immuno-equilibrium do not manifest detectable 
symptoms, this equilibrium is evidenced by multiple transmission of cancers from an apparently 
heathy donors57,58. Importantly, cancer clonal evolution and immunosurveillance may also have 
defining power over the capacity and location for secondary metastasis. Metastasis has been 
suggested to have a “seed and soil” relationship with secondary lesion sites59. In other words, 





immune environments must be permissive for cancerous growth59–61. In a particular mouse study, 
bone marrow derived VEGFR1+ hematopoietic progenitors arrive at pre-metastatic site long before 
primary tumor cells, and are important for tumor metastasis62,63. Neutrophils have been implicated 
in initiating metastasis as well64,65. 
1.4.2 Antitumor Immunity 
 Tumor immunity is an arms race between pro-tumor immune modulators and anti-tumor 
immune modulators. Besides TAMs, regulatory T cells (Treg), Th2, N2, DC2, myeloid-derived 
suppressor cells (MDSCs), and B cells have all been shown to be tumor promoting, whereas 
cytotoxic T cells, Th1, N1, DC1, NK, and M1 macrophages are tumor rejecting54,66. 
Immunological tumor rejections can be achieved through a wide range of mechanisms, including 
the use of certain chemotherapeutic agents that promote cancer antigen uptake and presentation67. 
Here we emphasize macrophage mediated T cell activities (Figure 4). Although DCs are more 
efficient APCs, macrophages can in theory stimulate T cell mediated anti-tumor response by 
fulfilling the three T-cell activation signals. For signal 1, engulfed antigen must be digested, 
processed, and loaded on MHCII for presentation to TCR. Then costimulatory molecules and 
activating cytokines constitute signal 2 and signal 3 respectively68. Upon activation, T cells can 
then trigger a cascade of antitumor responses including direct binding and killing specific antigen 






Figure 4. Macrophage Mediated Immunosurveillance 
Macrophage (dendritic cell shares similar process) mediated immunosurveillance can be classified into three 
stages, monocyte recruitment, differentiation & antigen uptake, and antigen presentation. At monocyte 
recruitment stage, DAMPs or PAMPs modify local endothelial cells, which in turn increase monocyte adhesion 
and promote extravasation from vasculature. At the site of inflammation, monocytes differentiate into 
macrophages and migrate under a chemotactic gradient. Upon encountering antigens, the microphage engulfs 
the foreign bodies by engaging various scavenger receptors and PRRs. The antigen is then broken down in 
lysosome then loaded onto MHC II. Peptide loaded MHCII serves as 1st of 3 signals required for T cell activation. 
Co-stimulatory receptors like CD80 and T cell stimulatory cytokines such as IL-6 or IL-1 β are 2nd and 3rd signal 
respectively. Upon successful antigen presentation and T cell activation, T cell mediated adaptive immunity can 





Chapter 2 – KPC PDAC Immune Landscape 
2.1 Introduction  
2.1.1 Pancreatic Ductal Adenocarcinoma 
 Pancreatic Cancer remains a lethal and prevent disease. Over 450,000 new cases were 
reported globally in 2018, the overall 5 year survival rate is about 10%, and for metastasized cases, 
the survival rate is less than 5% 69,70. Among all the subtypes, PDAC is the most common type of 
pancreatic cancer, accounts for more than 80% of all cases70. This considerable mortality rate is 
partly caused by asymptomatic disease progression, which leads to late diagonosis70. One report 
suggested the carcinogenesis for pancreatic cancer is remarkably slow, taking at least 10 years 
after the first genomic mutation to give raise to the first non-metastatic cancer cell, which would 
then take 5 more years to gain metastatic potentials71. In addition, the pancreatic cancer TME is 
pathologically complex. Dense fibrotic ECM protects cancer cells from chemotherapy, and TAMs 
release pyrimidines to inhibit gemcitabine efficacy72,73.  
2.1.2 Origins and Functions of TAMs 
 It was recently demonstrated that macrophages of both monocytic origin and embryonic 
origin contribute to PDAC TME remodeling74. Zhu and colleagues showed that monocyte derived 
TAMs have higher antigen uptake and presentation capacity, whereas embryonic TAMs had 
enhanced matrix remodeling transcriptional signatures74. Under physiological conditions, tissue 





inflammatory injuries call for monocyte extravasation and differentiation into macropahges32. It 
appears these cells of distinct linkages also conspire during tumorigenesis. Along with prior 
evidences of monocytic macrophages’ roles in cytotoxic T lymphocyte exclusion and poor patient 
survival, these findings depicts a complex immune landscape during tumor progression75,76.  
 Aimed at understanding the temporal immune landscape during tumorigenesis, we carried 
out orthotopic syngeneic PDAC study using the same Trp53R172H KrasG12D spontaneous cancerous 
KPC cells74,77.  
2.2 Materials & Methods  
2.2.1 Regulatory Compliance  
 Orthotopic PDAC model was carried out using female C57BL/6 mice (Jackson Laboratory) 
at 9 weeks of age . The study was reviewed and approved by institute Animal Care and Use 
Committee under protocol number M018A61.  
2.2.2 Pre-Surgery Preparations  
 Two days prior to the orthotopic injection, subjects underwent hair removal by Nair. The 
day before surgery, enrofloxacin was given at 5 mg/kg body weight subcutaneously (per 





2.2.3 Sample Preparation   
 Matrigel (Corning) scaffold was allowed to thaw on ice at 4 °C overnight. On the day of 
surgery, cancer cells were dissociated from culture and resuspended in PBS at 1000 cells/µL. 
10,000 cells were then mixed with equal volume of Matrigel, constituting 20 µL total injection 
volume. Surgical control group received equal volume of PBS/Matrigel without cancer cells. The 
cells were then kept on ice during the transport to animal holding facility.  
 
2.2.4 Laparotomy and Injection 
 Animals were incubated in isoflurane induction chamber until immobile, and general 
anesthesia was achieved using an isoflurane vaporizer and nose cone. Buprenorphine SR (0.5 
mg/kg) and the second dose of enrofloxacin were given subcutaneously.  
 2-cm incision was made on the left subcostal region along transverse plane first through 
dermis then peritoneum layer. Spleen was exposed by compressing against the opening. By 
carefully pulling the spleen, pancreas was exposed and the injection could be made. The test 
subjects received 10,000 KPC cells with Matrigel scaffold, and the control subjects received only 
scaffold. Spleen and pancreas were then placed back into cavity. The peritoneum and dermis were 
then sequentially sutured. The animals were then placed on heating pad until consciousness was 
regained. The post operation recovery was monitored at following day, and sutures were replaced 





2.2.5 Endpoint Processes  
 At each timepoint, subjects were euthanized. Primary tumor as well as liver, spleen, kidney, 
and inflated lungs were excised, placed in tissue cassettes, and fixed in formalin (VWR) solution 
overnight before replacing in PBS buffer. The lungs were inflated by injecting 1.5% agarose 
through trachea using a 18-G blunt fill needle (BD) . The agarose was melted in a microwave and 
maintained above 65 °C using a heat block. Needles and syringes were also prewarmed using the 
heat block to reduce blockage. The formalin fixed samples were then delivered to Oncology Tissue 
Services core for paraffin embedding, slicing, histology stains, and scanning.  
2.2.6 Primary BMDM Extraction 
 Mouse bone marrow derived macrophages (BMDMs) were harvested from C57BL/6J mice 
based on an established protocol78. In brief, mice were incapacitated with isoflurane (VET One, 
Fluriso) and euthanized in compliance with institute ACUC regulations. Hindlimb femurs and 
tibias were excised and sterilized with 70% ethanol. Proximal ends of the bones were severed, and 
a 26-G needle (BD) was inserted in distal ends. Marrow was flushed out with PBS (Corning) and 
dissociated by pipetting. The cells were then pelleted, washed, and seeded in T-75 flasks.  
 Primary mouse BMDMs were grown in DMEM (Corning 10-013-CV formulation) with 
10% HI-FBS and 100 U/mL Murine M-CSF (Prospec Protein, Cat # cyt-439). Fresh media was 
supplemented every two days, and the cell culture was maintained and expanded in culture for at 
least 7 days before assays. The protocol was validated to generate CD11b+ F4/80+ macrophages 







 To characterize the temporal immune cell landscape during tumorigenesis, we 
orthotopically implanted  the KPC GFP+ Luc+ cancer cells to C57BL/6 mice. Reporter tagged cells 
were used for the ease of tumor burden measurements. Prior experience working with orthotopic 
KPC models indicated an aggressive cancer phenotype and consequently short life span (4 weeks). 
Therefore, the experiment timeline was set for 3 weeks to profile B lymphocyte, T lymphocyte, 
and macrophage landscape within the primary tumor (Figure 5A). IHC staining showed a drastic 
increase of F4/80+ macrophage populations (Figure 5B), from almost nonexistent in WT control 
and PBS surgical control groups, to approximately 30% of total quantified pixel signals (Figure 
5C, 5D). This recruitment was also observed in kidney, liver, and spleen (Figure S1B).  
 Temporal depended CD4+ and CD8+ T cell enrichment was also observed, although no 
CD4+ and CD8+ T cells were detected in healthy WT control (Figure 5E, Figure S1A). Any tissue-
resident memory T cells (TRMs) that are important for immunosurveillance and homeostatic 
maintenance are likely below the detection limit79. Interestingly, CD45R+ B lymphocytes did not 
confer to any discernable pattern. While it is possible that B lymphocytes were not enriched during 
tumorigenesis, CD45R antibody also has higher background noise and less cell type specificities 
when compared to the other IHC antibodies used (Figure S1A).  
 Lastly, areas of CD11b+ macrophage infiltration coincides with areas of vasculatures at 1 
week post implantation. This result suggests that observed macrophage populations originated 
from the monocytic pool. Although it is not possible to speculate the degree of monocyte 










Figure 5. Temporal Immune Landscape during KPC Tumorigenesis 
(A) Overview of the experimental schedule for evaluating temporal immune landscape.  
(B) IHC stain of F4/80+ macrophages within pancreas, the primary cancer cell injection site  
(C) Representative images of IHC signal quantification using ImageScope. Positive signals are shown on a 
gradient from yellow to red corresponding to signal intensity. Negative signals are shown in blue, and 
backgrounds are uncolored.  
(D) Quantifications of F4/80+ and CD11b+ macrophages in pancreas. CD11b+ IHC for WT was not available.  
(E) Quantifications of CD4+, CD8+ T cells, and CD45R+B cells. 
(F) High magnification view of CD11b+ macrophages. Blood vessels are annotated in red, RBCs without 
endothelial structures are annotated in magenta.  
n = 1 subject, additional biological repeats are available but not processed. Scale bar, 50 µm.  
2.4 Discussion 
 In this study, WT control shows a healthy steady state immune cell abundance within the 
pancreas, whereas PBS surgical control accounts for the inflected trauma, possible infection, and 
potential Matrigel scaffold immune reactivities.  A significant enrichment of macrophage were 
seen in primary tumor site (indicated by F4/80+ and CD11b+ IHCs) and distal organs (indicated by 
F4/80+ IHC). This observation indicates KPC cells can modulate macrophage on a systematic 
level. It is possible that macrophages may also facilitate the remodeling of pre-metastatic niches 
like neutrophils or bone marrow hematopoietic progenitors62–65. 
 Furthermore, T cells (indicated by CD4+ and CD8+ IHCs) but not B cells (indicated by 
CD45R+ IHC) enrichment was observed during tumorigenesis. While T cell infiltration (either 
CD4+ and CD8+) did not reach the abundance level macrophages did, it is still difficult to speculate 
if one of these cell types facilitated the recruitment of the others. The difference in abundance 
between CD4+ and CD8+ lymphocytes is also smaller at week 3 than week 2. It is perceivable that 
a fraction of the CD4+ T cells are FoxP3+ regulatory T cells, which can suppress cytotoxic T 





 Working with reporter tagged cells may allow easier disease burden tracking, but the 
reactivity of these probes should also be considered. Specifically, the CTL epitope of luciferase 
may bind to murine IFN-γ receptors and trigger CD8+ T cell activities80,81. To address this concern, 






Chapter 3 – Macrophage Motility and Recruitment 
3.1 Introduction 
3.1.1 Immune Cell Migration  
 Coordinated migration is essential for immune cell function. During inflammation or 
pathogen invasion, non-tissue resident immune cells like neutrophils and monocytes need to 
extravasate from vasculature, and navigate through ECM82,83. The migration through blood vessel, 
known as the leukocyte recruitment cascade is relatively well understood. Local inflammation 
induces adhesion molecules in endothelial cells, promote leukocyte tethering, rolling, adhesion, 
crawling, and eventual transmigration82. For the second part, migration through ECM can be 
challenging, some adaption to remodel ECM or squeezing through matrix proteins are needed83. 
Here, we are taking a reductionist approach to examine the BMDM motility using 2D cell 
migration.  
3.1.2 Chemo Gradients  
 Once leukocytes leave blood vessel, the migration towards the site of inflammation within 
ECM is usually guided by chemotactic gradients82. At steady state, free of stimulations, 2D cell 
migration patterns are random when the cell maintains little intrinsic directionality (Figure 6A)84,85. 
The intrinsic directionality here is reflected under uniformly imposed signals that affect motility 
machineries but not directions84. If a stimulating signal (either positive or negative) were given 





of the cells, known as chemokinesis (Figure 6A) 84,86. In contrast, chemotaxis (and 
chemorepulsion) occurs when an asymmetric soluble factor gradient drives directional migration 
towards (or away from) the higher concentration (Figure 6A)84,85,87. Importantly, the same 
signaling molecule at different concentrations may drive both chemotactic attraction or 
repulsion87.  
 To understand the chemotactic relationship that leads to monocyte (and other immune cell) 
requirement to tumors, we performed a proof of concept study by carrying out cell-to-cell 
chemotaxis assay using MDA-MB-231 breast cancer cells and U937 monocytes.  
3.1.3 Random Walk Models 
 2D cell motility has long been described by cell speed and persistence using Persistent 
Random Walk (PRW) model86,88,89. Under physiological conditions, 3D environment is 
complicated by ECM topology, molecular composition of ECM, and other features such as ECM 
crosslinking, matrix stiffness and density83. Therefore the cell motility in 3D environment is 
dependent on specific ECM conditions as well as cell mediated matrix remodeling (i.e. expression 
of metalloproteinases). Its anisotropic nature does not meet the requirements of PRW. To factor in 
the differential migration pattern along the primary axis and an orthogonal secondary axis, 
Anisotropic Persistent Random Walk (APRW) model is better fitted for 3D migration88,89.  
 While 2D motility is evaluated for BMDMs, APRW provides better characterization of cell 






3.2 Material & Method  
3.2.1 µ-slide chemotaxis 
 Cells were seeded on µ-slide chemotaxis chip (ibidi) according to the manufacturer’s 
recommendations. U937 cells were seeded in collagen I (Corning, Rat Tail, High Concentration) 
at 2 mg/ml. The gel was allowed to set in the central channel at 37 ºC for one hour before liquid 
media or MDA-MB-231 cells were added to surrounding chambers.  
3.2.2 Primary BMDM Polarization 
 Primary BMDM extraction method is described in section 2.2.6. BMDM were cultured in 
the presence of M-CSF for 7 days. For M1 polarization, cells were cultured with 20 ng/mL IFN- γ 
(PeproTech, 315-05) and 100 ng/mL LPS (List Biological Lab, 421) for 24 hours. For M2 
polarization, cells were cultured with 20 ng/mL IL-4 (Prospec, cyt-282) for 24 hours. Fresh media 
were used for M0 macrophages. Polarization protocol is adapted from a literature reference90.  
3.2.3 Generation of KPC Conditioned Media  
 For high density and low density KPC conditioned media, 2 million and 1 million KPC 
cells were separately seeded in 10 mL of DMEM complete media in T-75 flasks. On day 2, 
supernatant was harvested and filtered using a 0.22 µm polyethersulfone syringe filter (Millipore). 
The conditioned media was stored at -80 ºC. At the time of treatment, conditioned media were 






3.3.1 Monocyte Recruitment 
 The in vivo study demonstrated the possibility of monocyte recruitment to a tumor site. To 
understand if cancers have chemotactic capacities, we carried out a proof of concept cell-to-cell 
chemotaxis assay using commercially available microfluidic channels (Figure 6B). When a 
gradient of cancer cell signaling molecules were created, U937 monocytes had a marginal increase 
in distance travelled towards MDA-MD-231 (Figure 6D). However, the relatively small cell 
number (15 cells towards from cancer cell chamber, 23 cells away) does not definitively suggest 
that a chemotactic relationship exists. When MDA-MD-231 cells were seeded in both chambers 
next to U937 cells (Figure 6C), the overall distance traveled seems to be smaller than that with 
only one chamber. Quantification of mean velocity per frame, mean-squared displacement over 
time, and diffusivity fitted through APRW model (Figure 6E – G) all suggested increased cancer 






Figure 6. U937 Chemotaxis using µ-Slide 
(A) Illustration of steady state and biased migrations.  
(B) Illustration of experimental setup using ibidi® µ-slide chemotaxis system. Cancer cell secreted signaling 
molecules are shown in magenta, fresh media is shown in blue. U937 monocytes were seeded in the 
narrow channel between two chambers.  
(C) U937 monocyte cell trajectories with cancer cells on both sides. Trajectories are normalized against 





(D) U937 monocyte cell trajectories with cancer cell on the left side. Trajectories are normalized against 
individual cell start point. 
(E) Population average velocity as measured by distance traveled per frame. Mean and standard deviations are 
shown. 
(F) Mean-squared displacement at 10 minute time lag for all cells. Mean and standard deviations are shown. 
(G) Diffusivity as calculated by anisotropic persistent random walk model for all cells. Mean and standard 
deviations are shown.  
Figures generated partially based on the online catalog of ibidi®. Unpaired t-test was performed.  
 
3.3.2 BMDM Motility  
 Upon differentiation with PMA, U937 derived macrophages are not motile (data not 
shown). This is likely an artifact of cell line model and polarization conditions. Primary BMDMs 
were therefore used to study the macrophage motility capacities at various polarization states and 
in response to cancer conditions.  
 BMDMs were treated with cytokine or tumor conditioned media for about 24 hours before 
tracking started. This allows sufficient time for M1 and M2 phenotype to be stably polarized90. At 
a population level, M2 polarized macrophages are significantly more mobile than M1 polarized 
and naïve M0 BMDMs (Figure 7A, 7B, 8B). Neither high density nor low density KPC 
conditioned media had an effect on the MSD of BMDMs (Figure 7B).  
 Furthermore, for most of the conditions tracked, the MSD grows as a function of time lag 
(𝜏) with an exponent of 1 (i.e. MSD ~ 𝜏𝛼 , 𝛼 = 1), suggesting free diffusion (Figure 8A). The 
Gaussian distribution of probability density function of cell displacement (PDF-dR) is also 
consistent with random and PRW model (Figure 8C).  The auto-correlation function of cell 
velocity (ACF) showed oscillation around zero, indicating where cell persistence time is less than 





time increments88. When the ACF is plotted for all the technical repeats for each condition, there 
is no clear exponential decay, suggesting BMDMs do not strictly follow PRW (Figure 8F).  
 
Figure 7. BMDM Motility Profiles 
(A) BMDM cell trajectories at frame 1, 50, and 100. Frames are 10 minutes apart. 
(B) Mean squared displacement for BMDMs. Calculations were done at 10 minute intervals.  
n = 4 technical repeats for M0 condition, n = 3 technical repeats for all other conditions. Unpaired t-test was 
performed. n.s. = non-significant, ****p <0.0001. 
 
  Consistent with the cell trajectories (Figure 8D – E), M0 naïve and M2 polarized BMDM 
motility profiles are more anisotropic. The velocity magnitude polarization profiles for M0 and 
M2 are more oval-like, whereas the M1 profile is more circular (Figure 8G), suggesting there is a 










Figure 8. BMDM Motility Parameters by Condition 
(A) Population averaged mean-squared displacement vs. time lag plot for all conditions.  
(B) Auto-correlation function of cell velocities at different time lag. Linear scale.  
(C) Probability density function of cell displacement. 
(D) Cell trajectories normalized by start point. Box depicts a 400-µm square. n = total cell number. 
(E) Cell trajectories of 16 randomly selected cells plotted on a 4x4 grid. 
(F) Auto-correlation function of cell velocities at different time lag. Log scale.  
(G) Velocity magnitude polarization profile for individual technical repeat. Primary axis of cell trajectory is 
aligned to x-axis, and non-primary axis of cell trajectory is aligned to y-axis.  
The plots are composites of 4 technical repeats for M0 condition and 3 technical repeats for all others. 
 
appear to be more polar than M1 phenotype as well, but their magnitudes of polarity cannot be 
distinguished between naïve M0 macrophages.  
3.3.3 Motility Hierarchical Clustering   
 It was also found that within each condition, there are large amounts of cell-to-cell 
heterogeneity. To better understand the effects of polarization and cancer conditions, hierarchical 
clustering was performed for both spatial distribution of APRW parameters (Figure 9) and time 
dependent motility activity profile (Figure 10)91.  
 For spatial clustering, persistence time for primary axis (Pp) and secondary axis (Pnp), 
diffusivity for primary axis (Dp) and secondary axis (Dnp), total diffusivity, anisotropy, and MSD 
at a short 10-minute time lag (MSD10) and a long 60-minute time lag (MSD60) were z-score 
normalized and used as clustering parameters. Trajectories from all conditions of BMDMs were 
pooled together and analyzed using MATLAB built-in ‘cosine’ distances and ‘ward’ linkages 
packages. Samples were iterated at different cluster numbers (Figure S2), and 6-cluster scheme 
was found to best explain observed trends (Figure 9A). For instance, if cluster P1 and P2 are 
compared, cluster P1 has markedly higher diffusivity and persistence along non-primary axis. P2 











Figure 9. BMDM Motility Clustering by Spatial Parameters 
(A) Heatmap of z-score normalized BMDM motility parameters at single cell level. Dendrogram represents 
hierarchical clustering based on ‘cosine’ distances and ‘ward’ linkages. Each row represents a cell, each 
column represents the APRW parameter calculated for the 107 frames (17.8 hours) the cell was tracked. Dnp, 
diffusivity along non-primary axis of migration; Pnp, persistence time along the non-primary axis of 
migration; Pp, persistence time along the primary axis of migration; Dp, diffusivity along primary axis of 
migration; Dtot, total diffusivity; MSD60, mean-squared displacement at 60 minute interval; MSD10, mean-
squared displacement at 10 min interval; Psi, Anisotropy.  
(B) Cell trajectories normalized against starting point, by cluster.  
(C) Cell trajectories of 16 randomly selected cells plotted by cluster.  
(D) Population average velocity vs frame of time. Velocity is measured by the distance traveled over the frame 
interval (10 min). 
(E) Fractional abundance of cells within each cluster, plotted by condition.  
(F) Shannon’s entropy as a measure of heterogeneity. Calculated for each technical repeat. 
Ordinary one-way ANOVA test (α = 0.05) was performed with Tukey’s multiple comparisons test. n.s. = non-
significant.  
 
This difference is fully captured in the cell trajectory plot (Figure 9B, 9C), where the P2 trajectories 
are flatter and more 1-dimensional in comparison to P1’s. 
 Within the 6 clusters, cluster P1 has highest motility based on persistence, diffusivities, 
and MSDs. Cluster P6 is the least mobile, in fact, the trajectories showed almost no effective 
displacement of the 17 hours of tracking (Figure 9B, 9C). Velocity as measured by population 
average displacement per time frame is also consistent with the decreasing motility from P1 to P6 
(Figure 9D). Furthermore, within each cluster, the motility is time invariant.  
 The fractional abundance of cells in each cluster is mapped out by condition (Figure 9E), 
and Shannon’s entropy was calculated as a measure of heterogeneity (Figure 9F, Appendix B). 
Notably, M2 phenotype was previously observed as more motile than other conditions, here this 
increased motility is associated with high fractional abundance in fast moving clusters like P1, P2, 
and low abundance in slow moving clusters P4, P5, and P6.  The overall cluster distribution of 












Figure 10. BMDM Motility Clustering by Temporal Resolution 
(A) Heatmap of z-score normalized 1-D displacement at single cell level. Dendrogram represents hierarchical 
clustering based on ‘cosine’ distances and ‘ward’ linkages. Each row represents a cell, each column 
represents a frame tracked. Two sequential frames are 10 minutes apart.  
(B) Example of a cell trajectory with respect to time. Initial time frame is shown in blue, final time frame is 
shown in yellow.  
(C) 1-D displacement vs time plot of the same cell shown in (B), termed (motility) activity profile here.  
(D) Cell trajectories normalized against starting point, plotted by activity cluster.  
(E) Cell trajectories of 16 randomly selected cells. 
(F) Mean-squared displacement vs time lag, plotted by activity cluster. 
(G) Fractional abundance of cells within each activity cluster, plotted by condition. 
(H) Shannon’s entropy as a measure of heterogeneity. Calculated for each technical repeat.  
Unpaired t test was performed. **p < 0.01. 
 
 Single cell BMDM motility data was also clustered based on the activity profile (i.e. the 
distance traveled per cell per frame) over the course of tracking. For individual cells, the 2D x, y- 
trajectories were converted to 1D distance (Appendix B). The activity profile of the cell can then 
be generated based on 1D distance at each time frame (Figure 10B, 10C). Three activity clusters 
(ACs) were generated to optimally classify the BMDM data. AC1 represents cells that were not 
moving, AC2 represents cells with transient and marginal movements, and AC3 represents cells 
with highest motilities (Figure 10D – F).  
 Once again, M2 BMDMs had high fractional abundance in the most motile cluster AC3, 
and low abundance in the least motile cluster AC1 (Figure 10G). Since about 70% of M2 cells 
were in AC3, M2 distribution is highly skewed (more homogeneous), and therefore has the lower 
Shannon’s Entropy (Figure 10H).  
3.4 Discussion 
 Whether it is directed chemotaxis, or uniform chemokinesis, motility is essential for 





modulating monocyte motility using U937 cell line model. While the exact mechanisms remain to 
be elucidated, cancer cell mediated reduction of immune cell motility has significant implications 
on immune evasion. Using primary bone marrow derived macrophages, it is clear that M2 cytokine 
polarized macrophage are more motile. Although in these studies, no significant differences were 
observed for BMDM motility of cancer conditioned media treated group and M0 naïve group, it 
is still possible for cancer cells to modulate macrophage motility.  
 A variety of factors could be responsible for these negative result. For instance, the tracking 
time interval could be too long to capture the transient motility features, the KPC cancer cells could 
lack specific signaling molecules, or the concentration of signaling factors are not produced to 
sufficient levels. Two densities of cancer cells were explored here in an attempt to capture the 
autocrine signaling process that is important for tumorigenesis. However, no apparent differences 
were observed between the high and low density conditioned media. It is possible these seeding 
densities still did not incorporate the pathologically relevant range, or the stiff substrate of tissue 







Chapter 4 – Macrophage Phenotypes 
4.1 Introduction 
 Macrophages are highly plastic and can be polarized into a range of phenotypes (Figure 2). 
While tumor associated macrophages do not confer to steady state phenotypes, they carry out vast 
pathological functions. It has been demonstrated that morphology of the macrophage can modulate 
its phenotype. Specifically, using an engineered substrate to form elongated cells can promote M2-
like expression profiles93. It is perceivable that the phenotype of macrophages can in turn be 
predicted by its morphology. Indeed, Rostam and colleagues have demonstrated the feasibility of 
accurately distinguishing M1 and M2 macrophages from DNA and actin stained fluorescent 
microscopy images using machine learning94.  
 Here we aim to elucidate if cancer conditioned media can polarize macrophages to distinct 
phenotypes as suggested by mRNA expression and morphology. MDA-MB-231 cancer 
conditioned media were used to treat U937 monocyte cell line derived macrophage, and KPC 
conditioned media were used to treat primary mouse BMDMs. Two seeding densities were used 
to generate cancer conditioned media.  
4.2 Materials & Methods  
4.2.1 U937 Derived Macrophages 
 For RNA extraction, U937 cells were seeded in a 6 well plate at 0.3~0.6 ∗ 106 cells per 





containing 1 µM Phorbl 12-myristate 13-acetate (PMA) (Sigma-Aldrich) were used to induce 
U937 differentiation into macrophage. On day 3, PMA containing supernatant is aspirated, and the 
cells were washed with PBS. Complete RPMI containing 50 ng/mL IFN- γ and 100 ng/mL LPS 
were added for M1. 50 ng/mL IL-4 and 50 ng/mL IL-13 were added for M2, and fresh media were 
added for M0. Cells were harvested on day 5. This differentiation protocol is based on published 
references95–97. The concentrations of PMA and polarizing cytokines were modified, and no 
apparent adverse effects were observed with these elevated concentrations.  
4.2.2 Generation of MDA Conditioned Media 
MDA-MB-231 conditioned media were generated same as the KPC conditioned media (Section 
3.2.4). At the time of treatment, conditioned media were added to equal volume of fresh media in 
order to prevent nutrient starvation. 
4.3 Results 
4.3.1 U937 Derived Macrophage 
 U937 derived macrophages exhibited few morphological differences upon polarization. It 
is not readily possible to distinguish cancer conditioned media treated macrophages based on 
manual classification alone (data not shown).  
 High density MDA-MB-231 conditioned media treated macrophages showed a significant 
upregulation of TNF-α, as well as suppressions of CXCL10 and IL1β when compared to naïve M0 





conditioned media treatment. This suggests the MDA-MB-231 cells can potentially modulate 
macrophage behavior differentially during different stages of tumor progression, although varying 
seeding density is an extremely simplified attempt to capture autocrine signaling changes during 
tumorigenesis.  
 CXCL10 is a chemokine ligand, and its binding can modulate adhesion and T cell 
migration. IL-1β is a proinflammatory cytokine that can facilitate T cell activation. Overall, the 
high seeding density MDA-MB-231 conditioned media appears to be promoting cancer escape, 
although TNF-α has been shown to both promote and suppress tumor growth98. 
 
Figure 11. U937 Derived Macrophage Polarization Profile 
RT-qPCR quantification of selective macrophage genes for U937 derived macrophages. Β-actin and TBP were 
used as reference genes. The expression was normalized against M0 naïve macrophage. 2 biological repeats 
were used for M0, 3 biological repeats were used for MDA231 conditioned media groups. Two – way ANOVA 
test (α = 0.05) was performed with Tukey’s multiple comparisons test. Unless specified, all pairs are non-






4.3.2 Bone Marrow Derived Macrophages 
 BMDMs exhibited 3 distinct morphologies: elongated, round, and fibroblast-like (Figure 
12A). Time-lapse images showed these morphologies are stable for hours, and round cell shapes 
do not appear to be caused by cell death or division. Upon cytokine induced polarization, M1 
BMDMs are significantly enriched in round cell shape, and M2 BMDMs are enriched in elongated 
morphology (Figure 12B). KPC conditioned media treated groups did not show as drastic 
enrichments like that of cytokine treated. However, both low density and high density KPC 
conditioned media had different morphology profiles when compared to M0 (Figure 12C). 
Specifically, conditioned media reduce the fractional abundance of round cells and increase the 
abundance of fibroblast like cells.  
 Furthermore, clustering analysis of mRNA data suggested these KPC CM treated cells are 
more M0 like, rather than M1 or M2-like. However, Ptgs1 which mediates the biosynthesis of 
prostaglandins and promotes angiogenesis is similarly upregulated in KPC CM treated and M2 
BMDMs. Interestingly, CM from a higher seeding density of KPC can induce different expression 
of 18s, Hprt, S100A4, and Cfd, which suggests potential roles in regulating translation, 











Figure 12. BMDM Phenotype 
(A) Representative bright field images of the three types of BMDM morphology  
(B) Fractional abundance of cells in each morphology, cytokine polarized groups vs control. n = 4 technical 
repeats.  
(C) Fractional abundance of cells in each morphology, KPC conditioned media treated groups. n = 4 technical 
repeats M0, n = 3 technical repeats for others.  
(D) Heatmap of mRNA expression quantified by RT-qPCR. Β-actin and RPL13A were used as reference genes. 
The expressions were z-score normalized for each gene target across all conditions. Red and green bars in 
the dendrogram represent M1 associated and M2 associated gene clusters respectively.   
Two – way ANOVA test (α = 0.05) was applied with Tukey’s multiple comparisons test. Unless specified, all 




 Conditioned media provides a simplified system to study paracrine signaling in cancer 
conditioned media. For U937 derived macrophages, MDA-MB-231 CM functions differently at 
different cancer seeding density. At low density, CMs treated macrophages have a more M0-like 
gene expression profile. At high density, markers responsible for tumor promotion start to appear. 
This is further supported in KPC – BMDM study, although some exceptions are present.  
 In BMDMs, CMs can also alter macrophages morphology distributions, although it is not 







Chapter 5 – Final Remark 
 Macrophages have been shown to infiltrate both primary sites and metastatic niches during 
tumorigenesis. Their role in maintaining tumor growth and immune evasion poses a serious 
clinical challenge. Here we speculated the origin of these macrophages and investigated cancer 
cells’ effect on macrophage recruitment, motility, morphology, and mRNA expression. While it is 
not yet clear how cancer conditions modulate macrophage motility, significant changes were seen 
for macrophage morphology and gene expression.  
 These are no doubt only a tip of the cancer immunomodulatory iceberg. Some of the key 
questions are still left unanswered. For starters, what signals are used to recruit macrophages, what 
signals are suppressing the pro-inflammatory activities, and what signals regulate the switch 
between early stage modulation and late stage modulation? 
 From an assay development perspective, if the macrophage morphology can be correlated 
with its motility and gene expression, it would be a beneficial predictor of tumor conditioning.  
 Overall, mechanistic insights into the recruitment and polarization of tumor associated 






Chapter 6 – General Materials & Methods  
6.1  Solutions and Buffers  
Table 2. Stock Solution Formulation 
 Stock Solution/Buffer Formulation 
6.1.1 FACS Wash Buffer 2% FBS, 0.1% Sodium Azide in 1x PBS 
pH 7.4 
6.1.2 FACS Fixation Buffer 1.6% PFA, 2% Glucose, 0.1% Sodium 
Azide in 1x PBS pH 7.4 
6.1.3 Fixation & Permeabilization Buffer 2% FCS, 1.6% PFA, 0.1% Sodium 
Azide, 0.01% Saponin in PBS pH 7.4 
6.1.4 FACS Permeabilization Buffer 2% FBS, 0.1% Sodium Azide, 0.01% 
Saponin in 1x PBS pH 7.4 
 
6.2 Cell Culture 
6.2.1 Serum Heat Inactivation 
 Fetal Bovine Serum (Corning) used for macrophage maintenance and experiments was 
heat inactivated to prevent unintended activation. The serum was heated to 56 °C for 30 minutes, 





6.2.2 Suspension Cells  
 THP-1 and U937 cell lines were grown in suspension in RPMI-1640 media (Gibco) 
containing 10% Heat-Inactivated Fetal Bovine Serum (Corning) (HI-FBS), 1% Pen Strep (Gibco), 
1% L-glutamine (200mM) (Gibco), 1% HEPES (1M) (Gibco). The cell cultures were incubated at 
37 °C with 5% CO2 and humidification. The cell lines were maintained at a density of less than 
1.2 ∗ 106 cell/mL and a passage number of less than 25 generations.  
 
6.2.3 Adherent Cells 
 MDA-MB-231, KPC and KPC Luc+ GFP+  cell lines were maintained in T-75 flasks with 
DMEM (Corning 10-013-CV formulation) containing 10% HI-FBS and 1% Pen Strep. KPC and 
KPC Luc+ GFP+ cells are generous gifts from Dr. Adrian Murphy and Dr. Elizabeth Jaffee. These 
cells originated from murine spontaneous cancer model of PDAC77. The adherent cells were 
maintained below confluency as indicated by visual inspection. The cell lines were kept at 37 °C 
with 5% CO2 and humidification.  
6.4 Real Time qPCR 
6.4.1 RNA Extraction 
 For U937 derived macrophages and BMDMs, cells were seeded in 6-well plate. Upon 





calcium and magnesium (Coring). Then 0.5 mL of TRIzol reagent (Invitrogen) were added to each 
well. Once cells are completely lysed, equal volume of 200 proof ethanol was added to each well. 
The samples are then kept on ice and immediately purified. 
 RNA purification was done using Direct-zol RNA Kit (Zymo Research) following 
manufacturer’s guidelines. In short, the RNA lysate was passed through spin columns (Genesee 
Scientific) by centrifugation at 14,000 RPM for 30 seconds using a tabletop centrifuge. The flow 
through was collected and disposed. RNA bound columns were washed twice with 400 µL Direct-
zol RNA PreWash buffer (Zymo Research) each time, then once with 700 µL RNA Wash Buffer 
(Zymo Research). The column was then dried by centrifugation at 14,000 RPM for 2 minutes. The 
RNA was then triple eluted with 20 µL of molecular biology grade water (Quality Biological) by 
collecting the flow-through and replacing it on top of column. RNA samples were immediately 
quantified and reverse transcribed.  
6.4.2 Reverse Transcription 
 RNA quality and quantity were assigned using ND-1000 Spectrophotometer (NanoDrop). 
RNA was then reverse transcribed using iScript cDNA Synthesis kit (Bio-Rad) according to 
manufacturer’s instructions. In short, 1 µg of RNA and water were added to 4 µL of 5x iScript 
Reaction Mix and 1 µL of reverse transcriptase to constitute a total reaction volume of 20 µL in a 





6.4.3 Quantitative PCR 
 Real Time qPCR was performed using 384-well plates (Bio-Rad) and Real Time Detection 
System (Bio-Rad, CFX384). Each well contains 1.5 µL of cDNA, 0.5 µL of primer mix, 3 µL 
water, and 5 µL of SYBR Green Master Mix (Bio-Rad). 4 technical repeats were performed for 
each target/condition pair.  
6.4.4 qPCR Data Processing  
 qPCR data were exported as .zpcr files. The data were then subsequently processed using 
Bio-Rad CFX Manger version 3.1.  
6.5 Flow Cytometry  
6.5.1 Fluorophore Panel Design 
 Fluorophore panels were designed using Fluorescence SpectraViewer (Thermo Fisher) and 
FluoroFinder to minimize spectral overlap. Fluorophores were further selected to be compatible 
with the BD FACSCanto cytometer.  
6.5.2 Sample Preparation 
 Cells were detached by incubating in TrypLE Express Enzyme (Gibco) at 37 °C. The 
detached cells are further dissociated, washed, and pelleted in a 15 mL conical tube. The 





staining, Fc receptors were first blocked by adding 5 µL of TruStain FcX (anti-mouse CD16/32 or 
human Fc Receptor Blocking solution, BioLegend) to the pellet and residual volume. The samples 
were then vortexed and incubated at room temperature for 15 minutes. Surface antigen targeted 
antibodies were then diluted in FACS Wash Buffer (Section 6.1.1) according to manufacturer’s 
recommended concentrations. Staining solution was directly added to the FcX blocked samples 
and incubated at 4°C for 30 minutes. Upon incubation, 3 mL of FACS wash buffer was then added 
to each sample for washing. Cells were pelleted and supernatant was discarded. Samples were then 
suspended in 0.35 mL of FACS wash buffer unless fixation is needed for delayed analysis or 
subsequent intracellular staining.  
 To fix the stained cells for analysis at another time, 0.35 mL of FACS fixation buffer 
(Section 6.1.2) was added instead of wash buffer.  
 For intracellular staining with EGR2, cells were fixed in Fixation & Permeabilization 
Buffer (Section 6.1.3) at 4°C for 40 minutes. The cells were then spun down and washed with 
permeabilization buffer (Section 6.1.4) for 3 times before incubating with intracellularly targeted 
antibodies at manufacturer’s recommended concentration and 4°C for 45 minutes. After pelleting 
and washing with FACS Permeabilization Buffer for 3 times, the cells were resuspended in FACS 
wash buffer.  
 
Table 3. List of Flow Cytometry Antibodies 





Rat Alexa Fluor 
647 
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Cyanine 7 



















Rat Alexa Fluor 
488 
erongr2 ThermoFisher Early growth 



























Mouse PE/Cy7 15-2 BioLegend MRC1, 
Macrophage 
Mannose 















6.5.3 Compensation Controls 
 To prepare single color compensation control, 3 µL of antibody was added to 1 drop of 
OneComp eBeads (ThermoFisher) and 300 µL of FACS Wash Buffer. 
 To prepare unstained control groups, the cells were harvested and incubated at the same 
conditions as that of antibody labeled samples, with an exception that no label or FACS wash 





6.5.4 Equipment Calibration  
 The stained samples were analyzed using BD FACSCanto located at the Johns Hopkins 
Integrated Imaging Center. The cytometer was maintained by the core facility, and calibrated with 
FACSDiva CS&T Research Beads (BD) before each use. The data were exported as .fcs files and 
analyzed using FlowJo 10.6.1.   
6.6 Microscopy 
6.6.1 Equipment  
 Florescence and bright field images were taken on a Nikon Ti-E microscope equipped with 
a motorized stage (Nikon), a Perfect Focus System (Nikon), a Lambda SC shutter controller (Sutter 
Instrument), and an Andor camera with a 10x magnification objective (Nikon S Fluor; numerical 
aperture, 0.5). For live cell imaging, the microscope stage is humidified, and its environmental 
conditions were kept at 37 °C and 5% CO2 with a stage top live cell box (Tokai Hit, model INU). 
For high magnification fluorescence imaging, a 60x oil immersion objective with apochromatic 
and flat field aberration correction (Nikon; Numerical aperture, 1.4). 
6.6.2 Motility Sample Preparation 
 Cells were seeded at 2,000 or 3,000 cells per 75 µL per well onto a 96-well tissue culture 
treated 96-well assay plate (Corning, costar 3603). Bordering wells were filled with PBS to 





attachment overnight, the plate was mounted on the microscope stage. Bright field images were 
recorded at every 10 min for 17 hours.  
 BMDM cells were seeded on 96-well untreated high performance glass plate (Cellvis P96-
1.5H-N) for motility tracking and subsequent high magnification fluorescence imaging.  
6.6.3 Fluorescence Sample Preparation 
 Cells were seeded at 3,000 or 5,000 cells per 75 µL per well onto a 96-well plate. Bordering 
wells were filled with PBS to minimize the edge well effects caused by differential evaporation 
rate across the plate. Upon attachment and treatment, media were aspirated using a multichannel 
pipette. Cells were fixed with 50 µL of 4% PFA per well at room temperature for 15 minutes, then 
washed with equal volume of PBS for 3 times. The samples were then stained with Hoechst 33342 
(Thermo Fisher) at 2 µg/mL and Alexa Fluor 568 Phalloidin (Invitrogen) at 1/500 of stock solution 
(or approximately 130 nM) in 50 µL of PBS per well. Upon 1 hour incubation in dark, the staining 
solution was aspirated and the cells were washed with PBS for 3 times. Then 75 µL of PBS was 
added to each well, and the plate is mounted on the microscope stage for imaging.  
6.6.4 Microscopy Data Processing 
 The microscopy imaging was registered in NIS Elements software (Nikon), and exported 





6.7 Analysis Software  
6.7.1 FIJI Cell Motility Tracking 
 Time course images were loaded into Fiji ImageJ as an image sequence99. Individual cell 
trajectories were registered using Manual Tracking plugin. Coordinate data were then exported as 
.csv files, which need to subsequently parsed for analysis using MATLAB.  
 
6.7.2 FlowJo 
 All flow cytometry data were analyzed using FlowJo 10.6.1 under the academic license 
with Johns Hopkins Integrated Imaging Center. 
6.7.2 Excel Parsing 
 .csv tracking files were parsed to remove header, convert X-, Y- positions to the unit of µm 
instead of pixel, and outputted as a .xlsx file. Excel parsing was done using a simple custom python 
script. 
6.7.3 Motility Clustering  
 Anisotropic Persistent Random Walk (APRW) model was used to fit the motility tracking 





protocol88. A driver function was written for the purpose of this study. The hierarchical clustering 
script was written based on prior work published in BioRxiv91.  
 All analysis scripts are available on GitHub repository under MIT license for open access 
(Wirtz-Lab/ HX_Motility_HierarchicalClustering). 
 
6.8 Figure Illustrations 
6.8.1 BioRender  
 Figure 1, Figure 4, and Figure 5A were created with BioRender.com under an individual 
academic license.  
6.8.2 GraphPad Prism 6 
 Column graphs and statistical tests were generated in GraphPad.  
6.8.3 Adobe Illustrator 
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Figure S1. IHC Scans for Immune Landscape Characterizations 
(A) Pathological slides of the pancreas. Same field of view was manually registered for each subject. CD11b+ 
IHC staining for wild type control was damaged during processing. CD45R background signals may have 
interfered with the quantification of wildtype and PBS surgical controls. Overall CD45R signals are below 
10%. Scale bar, 50 µm. n = 1 subject.  
(B) F4/80+ IHC staining for distinct organs. Enhanced F4/80 signals were observed for cancer cell implanted 

























Figure S2. Clustering Rationales   
(A) BMDM motility spatial clustering with 3 clusters as oppose to 8 clusters shown in Figure 9.  Same ‘cosine’ 
distances and ‘ward’ linkages were used for computing dendrograms.  
(B) Magnified view of cluster 2 from Figure S2A. This cluster has two distinct heatmap patterns P2-a and P2b, 
corresponding to the P3 and P4 from the 8 cluster dendrogram shown in Figure 9 respectively. The 
differential Dp, Dtot, Psi patterns between these two clusters suggests 3 cluster classification is 
underrepresenting the true heterogenicity of the population.  
(C) Shannon’s entropy calculated for 3 spatial cluster distribution and 6 spatial cluster distribution. Although 
the magnitude of spatial motility heterogenicity are higher in those with 6 cluster distribution, the overall 
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Figure S3. Flow Cytometry Confirm BMDM are CD11b+ F4/80+ Macrophage  
Unstained (left) and PBS surgical control groups BMDM (right) are shown in pseudo-color bivariate density 
plot. CD11b signal is shown on the y-axis, and F4/80 signal is shown on the x-axis. The populations shown are 
live singlets gated based on forward and sideward scattering. The majority (>95%) of the bone marrow derived 






Appendix A – List of Abbreviations  
Abbreviation Full Name/Definition Abbreviation Full Name/Definition 
APRW Anisotropic Persistent Random Walk Itgam Integrin Subunit Alpha M 
B7-2 CD86 Molecule KPC Mouse PDAC model cells 
BMDM Bone Marrow Derived Macrophage LDL Low-density lipoproteins 
C5aR1 Complement C5a Receptor 1 LPS Lipopolysaccharide 
CCR2 C-C Motif Chemokine Receptor 2 LTA Lipoteichoic acid 
CD Cluster of Differentiation M-CSF Macrophage colony-stimulating factor 
CD11b Integrin Subunit Alpha M M0 Naïve macrophage phenotype 
CD14 Monocyte marker M1 Pro-inflammatory macrophage phenotype 
CD206 Mannose receptor M2 Anti-inflammatory macrophage phenotype 
CD38 ADP-Ribosyl Cyclase 1 MCP-1 CCL2, Monocyte chemoattractant protein-1 
CD4 T helper maker MGL-1 Macrophage galactose-type lectin-1 
CD45R B cell marker MHC Major Histocompatibility Complex 
CD8 Cytotoxic T marker MHC II Major Histocompatibility Complex Class II 
CD80 B7-1 MMP Matrix metalloproteases 
CD86 B7-2 MR Mannose receptor 
CpG-ODN CpG oligodeoxynucleotides MRC1 Mannose Receptor C-Type 1 
CR3 Complement receptor 3 MSD Mean-squared displacement 
CSF1R Colony Stimulating Factor 1 Receptor NK Natural killer cell 
CXCR4 C-X-C Motif Chemokine Receptor 4 NO Nitric Oxide 
DAMP Damage‐associated molecular pattern  PAF Platelet-activating factor 
DC Dendritic cell PAMP Pathogen‐associated molecular pattern  
DMEM Dulbecco's Modified Eagle Medium PBS Phosphate-buffered saline 
ECM Extracellular matrix PD-L1/2 Programmed death-ligand 1/2 
EGF Epidermal growth factor PDAC Pancreatic ductal adenocarcinoma 
EGR2 Early Growth Response 2, transcription factor PDGF-BB Platelet-derived growth factor BB 
F4/80 EGF-TM7 famioy, pan macropahge marker PGE2 Prostaglandin E2 
FACS Fluorescence activated cell sorting PGN Peptidoglycan 
FcγRI Immunoglobulin Gamma Fc Receptor I PI3kγ Phosphoinositide 3-kinase γ 
GPI Glycosylphosphatidylinositol PMA Phorbol 12-myristate-13-acetate 
H&E Hematoxylin and eosin PRW Persistent Random Walk 
HLA-DR MHC Class II, DR RPMI Roswell Park Memorial Institute media 
IFN-γ Interferon gamma RT-qPCR Real Time quantitative PCR 
IgG1 Immunoglobulin G1 SDF1α Stromal cell-derived factor 1 alpha 
IL-10 Interleukin 10 SIRPα Signal regulatory protein α 
IL-12 Interleukin 12 TGF-β Transforming growth factor beta 
IL-13 Interleukin 13 Tie2 Tyrosine-Protein Kinase Receptor TEK 
IL-1ra Interleukin-1 receptor antagonist TLR Toll-like receptor 
IL-1β Interleukin 1 beta TME Tumor microenvironment 
IL-23 Interleukin 23 TNF-α Tumor necrosis factor Alpha 
IL-4 Interleukin 4 V(D)J Variable (V), diversity (D) and joining (J) genes 
IL-6 Interleukin 6 VEGF Vascular endothelial growth factor 








Appendix B – Key Equations used for Calculations 
Calculating 1-D displacement (x(t))  
𝑥(𝑡) =   √Δ𝑥2 + Δ𝑦2 
Δ𝑥 = 𝑥(𝑡) − 𝑥(𝑡 − 1);  Δ𝑦 = 𝑦(𝑡) − 𝑦(𝑡 − 1) 
Z-score normalization (z) 





Diffusivity along primary axis (𝐷𝑝) 







Diffusivity along secondary axis (𝐷𝑛𝑝) 







Total diffusivity (𝐷𝑡𝑜𝑡) 
𝐷𝑡𝑜𝑡 = 𝐷𝑝 + 𝐷𝑛𝑝 





Shannon’s entropy (S)  











APRW Parameters  
APRW parameters such as 𝑆𝑝, 𝑆𝑛𝑝, 𝑃𝑝, and 𝑃𝑛𝑝 were calculated by fitting the cell trajectory 









Appendix C – List of RT-qPCR Primers  






B-actin 5'- CATGTACGTTGCTATCCAGGC 5'- CTCCTTAATGTCACGCACGAT 
ARG1 5'- TGGACAGACTAGGAATTGGCA 5'- CCAGTCCGTCAACATCAAAACT 
CXCL10 5'- GTGGCATTCAAGGAGTACCTC 5'- TGATGGCCTTCGATTCTGGATT 
CXCR2 5'- CCTGTCTTACTTTTCCGAAGGAC 5'- TTGCTGTATTGTTGCCCATGT 
IL10 5'- ACGGCGCTGTCATCGATTT 5'- TGGAAGCTTCTGTTGGCTCC 
IL12B 5'- GCGGAGCTGCTACACTCTC 5'- CCATGACCTCAATGGGCAGAC 
IL1B 5'- ATGATGGCTTATTACAGTGGCAA 5'- GTCGGAGATTCGTAGCTGGA 
IL6 5'- ACTCACCTCTTCAGAACGAATTG 5'- CCATCTTTGGAAGGTTCAGGTTG 
MRC1 5'- GGGTTGCTATCACTCTCTATGC 5'- TTTCTTGTCTGTTGCCGTAGTT 
Siglec10 5'- TGGCTCAGAAGCGGAATC 5'- CCTCATTGGAACTTGACTTCTGC 
TBP 5'- GAGCCAAGAGTGAAGAACAGTC 5'- GCTCCCCACCATATTCTGAATCT 
TNFa set 1 5'- CCTCTCTCTAATCAGCCCTCTG 5'- GAGGACCTGGGAGTAGATGAG 














Arg1 5'- CTCCAAGCCAAAGTCCTTAGAG 5'- AGGAGCTGTCATTAGGGACATC 
B-actin set 1 5'- ATGAGCTGCCTGACGGCCAGGTCATC 5'- TGGTACCACCAGACAGCACTGTGTTG 
B-actin set 2 5'- GGCTGTATTCCCCTCCATCG 5'- CCAGTTGGTAACAATGCCATGT 
CD206 5'- CTCTGTTCAGCTATTGGACGC 5'- CGGAATTTCTGGGATTCAGCTTC 
CD38 5'- TCTCTAGGAAAGCCCAGATCG 5'- GTCCACACCAGGAGTGAGC 
Cfd 5'- CATGCTCGGCCCTACATGG 5'- CACAGAGTCGTCATCCGTCAC 
EGR2 5'- GCCAAGGCCGTAGACAAAATC 5'- CCACTCCGTTCATCTGGTCA 
Fpr1 5'- CCATTTGGTTGGTTCATGTGC 5'- CTTCTTGGCTAGGCTCACAGT 
Fpr2 set 1 5'- GAGCCTGGCTAGGAAGGTG 5'- TGCTGAAACCAATAAGGAACCTG 
Fpr2 set 2 5'- TCTACCATCTCCAGAGTTCTGTGG  5'- TTACATCTACCACAA TGTGAACTA  
Gpr18 5'- CACCCTGAGCAATCACAACCA 5'- AGTGACATTAACAAACAGCCCA 
Hprt set 1 5'- TGAAGAGCTACTGTAATGATCAGTCAAC  5'- AGCAAGCTTGCAACCTTAACCA  
Hprt set 2 5'- TCAGTCAACGGGGGACATAAA 5'- GGGGCTGTACTGCTTAACCAG 
Ifit3 5'- TCAGGCTTACGTTGACAAGGT 5'- CACACTTTAGGCGTGTCCATC 
IL6 5'- CTGCAAGAGACTTCCATCCAG 5'- AGTGGTATAGACAGGTCTGTTGG 
iNOS 5'- GTTCTCAGCCCAACAATACAAGA 5'- GTGGACGGGTCGATGTCAC 
Mgl2 5'- TTAGCCAATGTGCTTAGCTGG 5'- GGCCTCCAATTCTTGAAACCT 
Ms4a4c 5'- TGCAACTGCAAGCATAATGGG 5'- GCAATGGTTGAAGCGTCACA 
Ptgs1 5'- ATGAGTCGAAGGAGTCTCTCG 5'- GCACGGATAGTAACAACAGGGA 
RPL13A 5'- CGGACCGTGCGAGGTAT 5'- CACCATCCGCTTTTTCTTGTC 
S100a4 5'- TGAGCAACTTGGACAGCAACA 5'- CTTCTTCCGGGGCTCCTTATC 
Slc7a2 5'- GGCACCTTCGACGAACTTCTT 5'- CCCAAGCAGACTCTTTTACTCCA 








Johns Hopkins University (Baltimore, MD)       Anticipated: May 2020  
M.S. in Chemical and Biomolecular Engineering  
Thesis Project: Polarization and Recruitment of Tumor Associated Macrophages 
Supervised by Professor Denis Wirtz  
The Pennsylvania State University (University Park, PA)       Aug 2014 – Aug 2018  
B.S. in Chemical Engineering, Honors in Biochemistry and Molecular Biology  
Schreyer Honors College; Tau Beta Pi (Engineering Honor Society) 
Thesis: Characterization of PAD4 Inhibition and its Anti-Cancer Effects via mTOR Pathway 
Supervised by Dr. Yanming Wang 
University College London (London, United Kingdom)        Dec 2017 – Jun 2018  
Semester Abroad Program, Division of Biosciences  
AWARD 
Whitfield Research Endowment       |  Dean’s List    |  AIChE Freshman Recognition  
EXPERIENCE 
Graduate Researcher, Wirtz Lab, Institute for NanoBioTechnology, JHU           Sep 2018 – Present  
- Performed high-throughput screenings for cancer mediated human macrophage activation 
and polarization (qPCR, flow cytometry, and microscopy)  
- Implemented migratory characterizations using 3D collagen gel and spheroid systems  
- Conducted morphological and biomolecular phenotyping using primary Human PBMCs  
- Administered in vivo study using orthotopic mouse model of pancreatic cancer  
- Collaborated with both internal and external partners as a NIH U01 grant/project liaison  
- Organized weekly immunology journal club within the department  
Researcher, Wang Lab, Department of Biochemistry and Molecular Biology, PSU Dec 2016 – Jul2018  
- Examined anti-cancer effects of PAD4 enzyme inhibitors using Western Blot and qPCR  
- Created CRISPR/Cas9 constructs for generating knockout cell lines  
- Conducted pancreatic cancer cell growth inhibition studies using MTT assays  






Research Assistant, Bracewell Lab, Department of Biochemical Engineering, UCL  Jan – Jun 2018  
- Assisted on cell free protein synthesis projects using E. coli platforms  
- Evaluated codon usage variations among E. coli strains with respect to target proteins  
- Supported robust DASbox and Ambr 250 reactor runs while complying with GLP 
standards  
Upstream Intern, Vaccine Process Development and Commercialization, Merck & Co.   May – Aug 2017  
- Generated Design of Experiments to build continuous in-line metabolite analytical model 
using Raman spectroscopy probes  
- Constructed a scale-down model for a yeast fermentation process using 3L bioreactors  
- Authored experimental protocols, study design, and technical data packages  
- Planned and executed experimental studies while coordinating 4 scientists in a GMP 
facility  
Researcher, Curtis Lab, Department of Chemical Engineering, PSU      Nov 2014 – Dec 2016  
- Performed axenic extraction and symbiosis studies on more than 10 algal cell lines  
- Accomplished genetic transformation of 2 microalgae strains using agrobacterium 
mediated transformation for a waste water treatment project  
- Mentored 3 new researchers to the level of experimentally proficient and autonomous  
Researcher, Curtis Lab, Department of Chemical Engineering, PSU      Nov 2014 – Dec 2016  
- Performed axenic extraction and symbiosis studies on more than 10 algal cell lines  
- Accomplished genetic transformation of 2 microalgae strains using agrobacterium 
mediated transformation for a waste water treatment project  
- Mentored 3 new researchers to the level of experimentally proficient and autonomous  
LEADERSHIP 
Teaching Assistant, Molecular Thermodynamics, Department of Chemistry, Penn State 
Mentorship Chair, American Institute of Chemical Engineers, Penn State 
International Student Orientation (ISO) Leader, University Office of Global Programs, PSU 
Student Program Coordinator, University Office of Global Programs, Penn State  
PRESENTATION 
Xu H., Chu T., Huang Q., Walston J., Wirtz D., Wu P. “Characterization of the Motility and 
Morphology of Lymphocytes as Biomarker for Aging”. 8th International Conference 





Xu H., Willis N., Curtis W. “Monoculture Extraction and Permeability Constraints of 
Hydrocarbon Producing Colony Alga Botryococcus braunii”. 2016 College of 
Engineering Research Initiative Poster Symposium, Dec 2, 2016. State College, PA.  
Cook L., Fuente P., Xu H., Fodor, J., Milosavljevic B. “Photo-induced Solid State Proton 
Transfer from Pyranine to Hydroxyl Anion”. Department of Chemistry Poster 
Symposium, Apr 27, 2016. State College, PA.  
PUBLICATION 
Luo, S.*, Xu, H.*, Zuo, Y. et al. A Review of Functional Electrical Stimulation Treatment in 
Spinal Cord Injury. NeuroMolecular Medicine (2020)doi:10.1007/s12017-019-08589-9 
*Authors contributed equally  
SKILL 
Laboratory  
High-throughput Screening, Microscopy, Flow Cytometry, qPCR, Western Blot, 
Cloning, Mammalian Cell Culture, 3D Culture Systems, Bioreactor/Centrifuge Scaling  
 
Computer 
Python, MATLAB, SnapGene, Benchling, ELN, Microsoft Office, Aspen HYSYS  
 
Language 
Mandarin Chinese (native fluency)  
 
REFERENCE 
Available Upon Request  
 
 
